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normalized ratio (INR) monitoring in patients on vitamin K antagonists (VKA) on 
maintenance anticoagulation. Methods: This interim analysis is based on data of 
2863 patients enrolled in the PREFER in VTE registry in 7 Western European countries 
(France, Germany, Italy, Spain, UK, Austria and Switzerland). 1689 had DVT (only) 
and 1174 had PE (±DVT). Results: At 6-month follow-up, 51.5% of the patients were 
treated with VKA. INR measurements at 6-month follow-up (UK: 3 month) were 
performed in the hospital setting for 13.1% of these patients (most frequently in 
Spain 42.9%, UK 32.7%,, Italy 18.0%), in the anticoagulation center in 23.6% (in Spain 
40.0%, Italy 37.0%, UK 16.4%), in the physician’s office in 16.8% (Germany 90.7%, UK 
41.8%), by the patient self-measured in 4.9% (Spain 8.6%), or at biology labs or other 
institutions in 36.9% (France 92.4%). The patient’s mean travel distance to the INR 
site was 5.8 ±9.16 km overall, the range was 0-90 km (mean varied across countries 
from 2.4 to 7.7 km). Mean travel time was 14.3 ±18.4 min (across countries 5.7 to 
18.2 min). Patients most frequently used their private car/motorbike (50.8 %) or 
walked (16.4%). The mean number of INR measurements over the 6-month period 
was 16.8, the number of INR measurements per month was 2.8 ±1.2 overall (across 
countries 1.8 to 3.2). ConClusions: In the various countries, different institu-
tions are responsible for routine INR measurements. While biology labs are almost 
exclusively used in France, there is no equivalent for such institutions in other 
countries. INR self-measurement plays a minor role. Patients usually have the INR 
sites in their vicinity, and the average number of measurements shows little vari-
ation between countries.
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objeCtives: Atrial fibrillation (AF) is the most common cardiac arrhythmia, and 
accounts for one-third of hospitalizations for cardiac disturbances. The majority 
of descriptive data on management of AF patients are from western countries, 
with limited information available from the Middle East region. The objective of 
this study was to characterize treatment patterns and health resource utilization 
among AF patients in the Kingdom of Saudi Arabia (KSA) and United Arab Emirates 
(UAE). Methods: A retrospective chart review was undertaken at three hospitals 
in UAE and three in KSA, to identify AF patients diagnosed between January 2005 
and June 2010. Patient charts were sampled consecutively backwards by diagnosis 
date, from June 2010 until the target sample was reached. AF was identified based 
on ICD-9 code (427.31), from a sample of patients defined by any history of antico-
agulant use. Data on demographic and disease-related characteristics, treatment 
patterns, health resource utilization, and international normalized ratio (INR) con-
trol were abstracted from diagnosis until June 2012. Results: Among eligible AF 
patients (UAE, n= 157, KSA, n= 152), the majority were diagnosed with chronic AF 
(80.9% in UAE, 63.7% in KSA) as opposed to paroxysmal AF. Treatments prescribed to 
AF patients differed between countries: warfarin monotherapy was widely used in 
UAE (59.9%), while a variety of warfarin- and aspirin-based combination therapies 
were used in KSA, with no single dominant regimen. Warfarin + bisoprolol (12.5%) 
and aspirin + bisoprolol (10.5%) combination therapies were the most common 
regimens in KSA. Patterns of health care utilization also varied, with hospitalization 
and emergency room visits more common in KSA, and outpatient visits more com-
mon in UAE. ConClusions: Treatments and health resources used by AF patients 
varied between KSA and UAE. While some differences may result from differences 
in patient and disease characteristics, they likely also reflect variation in manage-
ment strategies across the regions.
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objeCtives: Individuals at high risk for cardiovascular events who fail to achieve 
treatment goal (LDL-C< 100 mg/dL) despite being on maximal lipid lowering treat-
ment qualify for apheresis, a procedure that costs approximately 40,000€ per patient 
per year in Germany. The current model aims to assess the ability of evolocumab 
(AMG 145), an investigational medication that is being evaluated in clinical trials, 
to reduce the proportion of patients requiring apheresis in Germany. Methods: 
Data on secondary prevention patients eligible for apheresis, excluding homozygous 
familial hypercholesterolemia patients, were extracted from the German IMS Disease 
Analyzer 2011-2013 database (n= 8,262) and included in the analysis. The calculated 
mean LDL-C reductions observed in the DESCARTES and LAPLACE-2 evolocumab tri-
als, ranging from 59.3% (95% CI [54.9%, 63.8%]) to 72.3% (95% CI [69.1%, 75.4%]), were 
applied to baseline LDL-C levels of the identified patient-profiles, following a proba-
bilistic approach. The goal for such patients was LDL-C< 100 mg/dL, as defined in the 
German lipid association (DGFF) guideline. Results: The mean ± standard deviation 
LDL-C levels of the sample decreased from 150.2 ± 32.9 mg/dL at baseline to 61.1 ± 
13.8 mg/dL (DESCARTES) and to 41.7 ± 9.5 mg/dL (LAPLACE-2) after evolocumab treat-
ment. From an initial proportion of 100% of patients eligible for apheresis at baseline, 
evolocumab treatment led to a proportion of 1% (DESCARTES) and 0% (LAPLACE-2) 
of patients requiring apheresis. Thus, in the analyzed population, apheresis-related 
costs could be largely reduced. ConClusions: The use of evolocumab in the treat-
ment algorithm of high-risk patients not at LDL-C goal could allow reducing the 
invasive, time-consuming, burdensome and costly weekly apheresis treatments. As a 
result, significant savings of apheresis-related costs could be achieved by the German 
Health Care System.
reduction. A predefined questionnaire was delivered to physicians’ and primary 
care payers’ (namely members of the regional health authorities) to survey their 
opinions about the value of this tool. Results: Overall opinion from 30 physicians 
and 11 primary care deciders (geographically distributed) was positive, averaging 
3.9 in a likert scale from 1 (strongly disagree) to 5 (strongly agree). Physicians aver-
aged 4 while primary care payers’ was 3.7. 71% of respondents ranked 4 to 5 in 
this overall assessment of the tool. Regarding more specific topics using the same 
likert scale, global, physicians’ and primary care deciders’ responses averaged as 
following, respectively: Utility of the tool: 3.6, 3.6 and 3.6; Relevance of the tool: 3.9, 
3.9 and 3.9; Value of the tool to understand LDL-C treatment targets: 4.0, 4.2 and 
3.6. ConClusions: This approach is useful to understand user’s opinions about a 
tool which aims primarily to raise awareness on the importance of the LDL-C reduc-
tion. Available evidence demonstrates that health care stakeholders in Portugal still 
need to understand the public health potential of LDL reduction. This tool might be 
of great value to address this need.
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objeCtives: Clinical guidelines recommend ACEIs (angiotensin converting enzyme 
inhibitors), ARBs (angiotensin receptor II blockers) for patients intolerant to ACEI, beta 
blockers (BBs), aldosterone antagonists (AAs) and diuretics as the pharmacological 
treatment for heart failure (HF). This study assesses the treatments prescribed within 
30 days post diagnosis among HF patients in a real world setting based on an admin-
istrative claims database in the US. Methods: This was a retrospective cohort study 
conducted using MarketScan database. Adult patients having ≥ 2 HF-related medical 
claims or 1 hospitalisation with primary HF diagnosis between April 2009 and March 
2012, and with a minimum of 12 months pre- and post-index continuous medical 
and pharmacy eligibility were included. Index date was defined as the first HF-related 
medical claim between April 2009 and March 2012. Patients with HF diagnosis in the 
12 months pre-index period were excluded. Demographics, clinical characteristics 
and index treatment (defined as a 30 days window period after HF diagnosis) were 
analysed. Results: Among 121,904 patients included in the analysis, 48.3% were > 75 
years of age and 35.0% were 18-64 years of age. Diabetes (27.0%), CV related condi-
tions (26%) and COPD (16.3%) were the most prevalent comorbidities. Overall, 37.6% 
patients were not prescribed any treatment related to HF within the first 30 days 
after HF diagnosis (no HF severity available). Among those prescribed treatment, the 
following treatment breakdown was observed: ACEIs, 29.3% of patients; ARBs, 8.5%; 
BBs, 46.6%; AAs, 7.4%; and diuretics, 45.7%. Prescription of fixed dose combination of 
ACEIs with diuretics or ARBs with diuretics was very limited. ConClusions: Findings 
suggest that a substantial proportion of patients do not receive HF specific medica-
tions following the month of diagnosis. Further research is necessary to explore the 
reasons for lower than expected HF medication claims in these patients considering 
their high risk for morbidity and mortality.
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objeCtives: Benzodiazepines (BZD) are often administered to patients with arterial 
hypertension in addition to antihypertensive agents. The aim of this study was to 
analyze patterns of BSD usage among hypertensive outpatients in Serbia according 
to sex and age. Methods: Data on BZD issued on prescription for the International 
classification of diseases (ICD) code I10 (essential arterial hypertension) were col-
lected from all state-owned pharmacies in Novi Sad (population 350,000) from 
September 2011 to February 2012. Consumption was calculated using the ATC/
DDD methodology. Results: BZD accounted for 2% of all drugs issued in treat-
ment of hypertension. The total amount of BZD issued was 2.27 DDD/1000inh/day. 
Bromazepam (51.38 %) and diazepam (37.56 %) were the most commonly used BSD 
and accounted for almost 90% of all BSD utilized. Lorazepam accounted for 8.36% 
of total consumption. Other agents (alprazolam, nitrazepam, midazolam, klonaz-
epam) accounted for less than 3% altogether. The BZD consumption increased with 
patient’s age – 91% being prescribed to the patients over the age of 50. Consumption 
was highest in age group 70-80 years. BZD were more often prescribed to female 
(68.63%) than to male outpatients (31.37%). ConClusions: This study confirmed 
consumption of BZD among outpatients with hypertension. It is most common 
in hypertensive female and elderly population. However, since the benefits of 
BZD administration in hypertension control remain unclear, the adequacy of this 
practice is questionable. This work was supported by the Ministry of Science and 
Technological Development, Republic of Serbia, project No. 41012.
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objeCtives: In patients with acute deep venous thrombosis (DVT) or pulmonary 
embolism (PE) there is a lack of comparative data on the logistics of international 
